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ST elevation myocardial infarctionBackground: No-reﬂow (TIMI b3) during primary PCI (PCI) for STEMI occurs in 11–41% of cases, indicates poor
myocardial tissue perfusion, and is associated with a poor outcome. We aimed to determine predictors and
12 month outcomes of patients who developed no-reﬂow.
Methods:Weanalysed the PCI database of The Canberra Hospital and identiﬁed 781 patients whounderwent pri-
mary PCI during 2008–2012. Follow-up at 12 months was with letter, phone call and review of hospital records.
Results:No-reﬂowwas observed in 189 patients (25%) at the end of the procedure. Patients with no-reﬂowwere
older (64 vs. 61 years, p = 0.03). No-reﬂow patients were more likely to have initial TIMI ﬂow b3 (89% vs. 79%,
p = 0.001), thrombus score ≥ 4 (83% vs. 69%, p = 0.0001), higher use of glycoprotein IIb/IIIa inhibitors (57% vs.
48%, p= 0.03) and longermedian symptom to balloon time (223min vs. 192min, p= 0.004). No-reﬂowwas an
independent predictor of mortality (HR 1.95, CI 1.04-3.59, p = 0.037) during 12 month follow-up. On multivar-
iate analysis, age N 60 years, thrombus score ≥ 4 and symptom to balloon time N 360min were independent pre-
dictors of no-reﬂow. In 17% of cases of no reﬂow, it occurred only after stent insertion.
Conclusions:No-reﬂowoccurred in 25% of STEMI patients undergoing primary PCI andwasmore likelywith older
age, high thrombus burden and delayed presentation. No-reﬂow was associated with a higher risk of death at
12 month follow-up.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Primary percutaneous coronary intervention (PCI) is the reperfusion
strategy of choice in restoring blood ﬂow to the occluded coronary ar-
tery in patients with ST elevationmyocardial infarction (STEMI) [1]. Im-
paired coronary ﬂow (Thrombolysis inMyocardial infarction grade b 3)
despite restoration of epicardial coronary artery patency in the absence
of any spasm or dissection is known as no-reﬂow [2]. It is thought to be
caused by a combination of ischemic endothelial injury that obstructs
the capillary lumen, neutrophil accumulation, reactive oxygen species
and distal embolization of atherothrombotic debris [2,3]. No-reﬂow oc-
curs in 11–41% of STEMI patients treated by primary PCI and is associat-
ed with poor left ventricular function, adverse clinical events and death
[2,3]. A number of clinical, serologic and angiographic parameters have
been shown to be associated with no-reﬂow [3].
The results of clinical trials testing a number of treatment strategies
for no-reﬂow have been conﬂicting and there is no deﬁnitive treatmentllow, Department of Cardiology,
eliability and freedom from bias
land Ltd. This is an open access articlof no-reﬂow once it has occurred [4–8]. In the absence of an effective
treatment strategy, it is crucial to prevent no-reﬂow by knowing the
predictors or risk factors of no-reﬂow. Previous studies have identiﬁed
various predictors of no-reﬂow, which are different between studies,
likely due to the differences in the populations being studied [2,3,9,
10]. We aimed to identify the clinical and angiographic factors that pre-
dicted no-reﬂow in our contemporary cohort of consecutive patients
with STEMI treated with primary PCI, and to determine the impact of
no-reﬂow on mortality.
2. Methods
2.1. Study population
We reviewed the PCI database of The Canberra Hospital and identi-
ﬁed 781 patients who presented as acute ST elevation myocardial in-
farction during 2008 to 2012. The creation and maintenance of the PCI
registry was approved by the ACT Health Human Research Ethics Com-
mittee and all patients providedwritten consent for inclusion in the reg-
istry and follow-up. Demographic and procedural characteristics and
the indication for the procedure were prospectively recorded and en-
tered into the database. TIMI ﬂow was measured retrospectively by a
single experienced cardiologist who was blinded to the clinical data.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of patients with normal ﬂow and no-reﬂow.
No-reﬂow
n = 189 (25%)
Normal ﬂow
n = 575 (75%)
p value
Mean age (years) 64 ± 13 61.4 ± 13 0.023
Female sex 43 (23%) 131 (23%) 0.98
Diabetes 38 (20%) 97 (17%) 0.32
Hypertension 79 (42%) 236 (41%) 0.85
Smoker 42 (22%) 169 (29%) 0.052
Ex-smoker 36 (19%) 100 (17%) 0.61
Hyperlipidaemia 60 (32%) 171 (30%) 0.60
Family history of IHD 43 (23%) 154 (27%) 0.27
BMI 27.7 ± 5.4 27.2 ± 4.6 0.91
Prior PCI 27 (15%) 96 (17%) 0.42
Prior CABG 12 (6%) 22 (4%) 0.16
BMI = body mass index, CABG = coronary artery bypass graft, IHD = ischemic heart
disease,
PCI = percutaneous coronary intervention.
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specialist and acute care to more than 700,000 people. We perform ap-
proximately 2000 diagnostic angiograms, 800 PCI and 150 primary PCI
procedures per year.
2.2. Procedure
PCI procedures were performed through the femoral or radial artery
using 6 Fr sheaths. All patients were treated with dual antiplatelet ther-
apy including aspirin and either clopidogrel or prasugrel prior to the
procedure. Aspirin was continued indeﬁnitely and clopidogrel or
prasugrel was recommended for 12 months. Intravenous heparin was
administered to achieve an activated clotting time of 300 s. Adjunctive
pharmacotherapy including the use of glycoprotein IIb/IIIa inhibitors
and the type of stent were at the discretion of the interventional cardi-
ologist. All patients underwent pre and post intervention ECG.
2.3. Assessment of coronary angiograms
All angiograms were reviewed by an experienced cardiologist
blinded to the patients' outcome and follow-up status. Epicardial coro-
nary blood ﬂowwas quantiﬁed visually using the Thrombolysis inMyo-
cardial infarction (TIMI) ﬂow grade classiﬁcation [11]. Initial TIMI ﬂow
was assessed at the beginning of the procedure prior to wire insertion
and ﬁnal TIMI ﬂow was assessed at the end of the procedure. No-
reﬂow was deﬁned as TIMI grade b3 at the end of the procedure in
the absence of any coronary dissection or spasm. In the sub-group of pa-
tients that developed no-reﬂow, coronaryﬂowwas also assessed imme-
diately before and after stent insertion in order to assess the inﬂuence of
stent deployment on no-reﬂow. Coronary ﬂow immediately before and
after stent insertion was quantiﬁed by TIMI frame count in order to ob-
jectively determine any change in ﬂow after stent insertion [11]. For this
purpose, TIMI frame count (TFC) of N20 was deﬁned as no-reﬂow. All
angiograms were recorded at 15 frames/s.
Myocardial blush grading was not performed as most angiogram
ﬁlms were not acquired long enough to estimate the myocardial blush
grade. Thrombus burden was estimated by using the thrombus scoring
system proposed by the TIMI group [12].
2.4. Deﬁnitions and endpoints
The primary clinical endpoint for the study was all-cause mortality
at 12 months. Other outcomes measured were re-infarction, stent
thrombosis, transient ischemic attack (TIA) or cerebrovascular event
(CVA), target lesion PCI, and coronary artery bypass grafting (CABG).
MACE was deﬁned as the composite of death, stent thrombosis, target
vessel revascularization, re-infarction and stroke. Stent thrombosis
was deﬁned as deﬁnite stent thrombosis by angiography. MI was de-
ﬁned according to the third universal deﬁnition of MI [13]. Stroke was
deﬁned as a new focal neurological deﬁcit following catheterisation or
intervention lasting more than 24 h and conﬁrmed by imaging. Cardio-
genic shock was deﬁned as a systolic BP b90 mm Hg or a requirement
for inotropic therapy.
Symptom onset time was the time recalled by the patient as the
onset of symptoms. First medical contact (FMC) was deﬁned as the
time of arrival of ambulance at the scene or patient arrival time at the
ﬁrst emergency department. Balloon time was deﬁned as the time of
ﬁrst device used for reperfusion.
2.5. Data collection and follow-up
In-hospital clinical eventswere recorded by a research nurse prior to
discharge. Long term follow-up was conducted by letter, phone calls
and review of hospital records at 12 months. In case of adverse events,
further details were obtained from the patient's medical records, physi-
cian or from other hospitals. We also obtained approval to access theAustralian Institute of Health and Welfare National Death Index to ob-
tain accurate data on vital status and date of death for our patients.
We supplied the patients' name, date of birth and residential address
and these parameters were matched with data on the national death
index. We accepted a match when a patient on the national death
index had the same name and date of birth as a patient in our registry.
2.6. Statistical analysis
Patients were categorised as having “normal ﬂow” or “no-reﬂow”
based on the ﬁnal TIMI ﬂow at the end of the procedure. The baseline
clinical characteristics and procedural characteristics of the two groups
were compared using the Student's t test for continuous variables and
the chi-square test for categorical variables. Cox proportional hazard
multivariate analysis was performed to determine predictors of death
during follow-up. We also performed a multivariate analysis to deter-
mine predictors of no-reﬂow. Variables in the model included
age N 60 years, gender, smoking status, diabetes mellitus, hypertension,
cardiogenic shock, anteriorMI, culprit vessel, thrombus score, three ves-
sel disease, glycoprotein IIb/IIIa inhibitor use, use of N1 stent, total stent
length, type B2/C lesion, symptom to ﬁrstmedical contact and symptom
to balloon time. A p value b0.05 was considered signiﬁcant. All statisti-
cal analyses were performed using SPSS Statistics forWindows, Version
22.0.
3. Results
Primary PCI was performed in 781 patients during 2008–2012. Sev-
enteen patients were excluded for the following reasons; 1 patient had
intravascular ultrasound (IVUS) and percutaneous coronary interven-
tion (PCI) was not required, 12 patients had unsuccessful PCI, 4 patients
did not have long term follow-up although they had no in-hospital ad-
verse events. Therefore we had 764 patients with long-term follow-up
for analysis. No-reﬂow was seen in 189 (25%) patients at the end of
the procedure. The clinical characteristics of patients with ﬁnal no-
reﬂow or normal ﬂow are shown in Table 1. Patients with no-reﬂow
were older (64 ± 12 years vs. 61 ± 13 years, p = 0.02) and there was
a trend for them to be less likely to be smokers (22% vs. 29%, p=0.052).
The procedural characteristics are shown in Table 2. The normalﬂow
and no-reﬂow groups were similar in terms of the culprit vessels in-
volved, proportion of patients with three vessel disease (21% vs. 20%,
p = 0.77) and total stent length per patient (24 ± 12 vs. 22.1 ±
11 mm, p = 0.06). Use of prasugrel (23% vs. 24%, p = 0.95) and drug
eluting stents (22% vs. 22%, p = 0.96) was similar between the two
groups. Balloon angioplasty alone was used more often in no-reﬂow
group (10.6% vs. 2.6%, p = b0.0001). Patients with no-reﬂow were
more likely to have initial TIMI ﬂow of 0–1 (77% vs. 64%, p = 0.0007)
and thrombus score ≥4 (83% vs. 69%, p = 0.0001). Glycoprotein IIb/
Table 2
Procedural characteristics of patients with normal ﬂow and no-reﬂow.
No-reﬂow
n = 189
(25%)
Normal ﬂow
n = 575
(75%)
p value
Radial access 10 (5%) 23 (4%) 0.46
Culprit vessel:
LAD/diagonal 77 (41%) 249 (43%) 0.49
LCx/marginal 28 (15%) 85 (15%)
RCA 78 (41%) 233 (41%
Bypass graft 6 (3.2%) 8 (1.4%)
Initial TIMI ﬂow 0–1 146 (77%) 369 (64%) 0.0007
Thrombus score ≥4 156 (83%) 391 (69%) 0.0001
3 Vessel disease 39 (21%) 112 (20%) 0.77
Prasugrel 44 (23%) 135 (24%) 0.95
Glycoprotein IIb/IIIa 107 (57%) 273 (48%) 0.03
DES use 38 (22%) 124 (22%) 0.96
N1 Stent used 50 (30%) 147 (27%) 0.40
Balloon angioplasty only 20 (10.6) 15 (2.6%) b0.0001
Total stent length (mm) 24.0 ± 12 22.1 ± 11 0.06
Cardiac arrest 6 (3%) 6 (1%) 0.06
Cardiogenic shock 11 (6%) 21 (4%) 0.21
Type B2/C lesion 159 (84%) 478 (83%) 0.71
Median symptom to FMC, (IQR) 105 (53–199) 81 (45–146) 0.004
Median FMC to balloon time, (IQR) 97 (70–140) 93 (72–135) 0.12
Median symptom to balloon time,
(IQR)
223
(156–406)
192
(135–291)
0.004
FMC= ﬁrstmedical contact, IQR= interquartile range reported as 25% to 75% range, LAD=
left anterior descending artery (if diagonal artery was culprit artery it was included in LAD
group), LCx = left circumﬂex artery (if obtuse marginal artery was culprit artery it was in-
cluded in LCx group), RCA = right coronary artery, DES = drug eluting stent.
Table 4
Independent predictors of death on multivariate cox regression analysis.
Variable Hazard ratio Conﬁdence interval p value
Cardiogenic shock 11.1 5.9–19.9 b0.0001
Age N 60 years 2.87 1.54–5.88 b0.0005
Initial TIMI ﬂow 0–1 2.29 1.12–5.31 0.021
No-reﬂow 1.79 1.04–3.04 0.037
Smoker 0.34 0.12–0.80 0.011
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48%, p= 0.03). Patients who experienced no-reﬂow had a longermedi-
an symptom to ﬁrst medical contact time (105 min vs. 81 min, p =
0.004) and symptom to balloon time (223 min vs. 192 min, p =
0.004). Out of the 189 patients with no-reﬂow, an analysis of TIMI
ﬂow before and after stent deployment was performed in 150 patients
with suitable images. In 25 of these 150 patients (17%), no-reﬂow oc-
curred immediately after stent implantation.
Clinical outcomes are shown in Table 3. Patients with no-reﬂow had
a higher 12 month mortality (13% vs. 6%, p = 0.004). There was no dif-
ference in target lesion PCI, re-infarction, stent thrombosis, TIA/CVA and
CABG at 12 months. There was a higher MACE at 12 months in patients
with no-reﬂow (18% vs. 11.5%, p = 0.025).
On multivariate analysis (Table 4), independent predictors of mor-
tality were cardiogenic shock, age N60, initial TIMI ﬂow 0–1 and no-
reﬂow. Surprisingly, smoking status was associated with a lower risk
of death. In our cohort smokers were on average 11 years younger
than non-smokers (65 ± 13 vs. 54 ± 9, p = b0.0001). The other base-
line characteristics were similar between the two groups.
We performed a furthermultivariate analysis to determine indepen-
dent predictors of no-reﬂow (Table 5). We found that thrombus scoreTable 3
Clinical outcomes of patients with normal ﬂow and no-reﬂow at 12 months.
No-reﬂow
n = 189 (25%)
Normal ﬂow
n = 575 (75%)
p value
Mean days follow-up 321 ± 208 325 ± 211 0.80
Death 24 (13%) 34 (6%) 0.004
Stent thrombosis 3 (1.6%) 8 (1.4%) 0.85
Re-infarction 8 (4.2%) 20 (3.5%) 0.64
Target lesion PCI 7 (3.7%) 20 (3.5)% 0.88
CABG 4 (2.1%) 8 (1.4%) 0.50
TIA/CVA 1 (0.5%) 2 (0.35%) 0.76
MACE 34 (18.0%) 66 (11.5%) 0.025
CABG = coronary artery bypass graft, PCI = percutaneous coronary intervention, TIA =
transient ischemic attack, CVA = cerebrovascular accident, MACE = major adverse car-
diovascular events.≥4, symptom to balloon time N360 min, and age N60 years were signif-
icant predictors of no reﬂow in STEMI patients.
4. Discussion
In our cohort no-reﬂow was seen in 25% of patients with STEMI un-
dergoing primary PCI. The reported incidence of no-reﬂow varies de-
pending upon the population being studied. When including all
patients undergoing PCI for any indication, the incidence has been re-
ported to be around 2.3–4.8% [2,9]. The reported incidence is higher in
patients with STEMI and ranges from 11 to 41% [2].
No-reﬂow is a strong prognostic marker and has been shown to be
associated with worse short and long term mortality [10,14]. The poor
prognosis with no-reﬂow is due to larger infarct sizes, adverse left ven-
tricular remodelling and reduced left ventricular systolic function [14].
In our study no-reﬂow was one of the independent predictors of
death at 12 months. Interestingly, smoking status was associated with
a lower risk of death. We believe that this is mainly because smokers
were on average 11 years younger than non-smokers, even though we
tried to correct for this in our multivariate analysis.
Several studies have tested various treatments for no-reﬂow after it
has occurred, but these therapies have been unsuccessful. A recent
Cochrane review of 10 randomised studies showed no beneﬁt from
adenosine or verapamil in reducing no-reﬂow, non-fatal myocardial in-
farction or all-cause mortality and there was some evidence of increase
in side effects with adenosine [5]. Use of distal embolic protection de-
vices in native coronary arteries has also failed to show an improvement
in myocardial perfusion or reduction in infarct size in patients with
STEMI [6–8]. It is therefore crucial to try and prevent no-reﬂow from oc-
curring in the ﬁrst place. In our cohort, therewere three risk factors pre-
dictive of no-reﬂow. Firstly older patients (age N 60 years) were more
likely to have no-reﬂow which has also been shown in other studies
[2,9,10]. Intravascular ultrasound (IVUS) studies have shown that high
burden of mixed atheromatous plaque is associated with a higher like-
lihood of no-reﬂow [15]. It is also known that elderly patients have a
higher plaque burdenwith high necrotic core on IVUS [16]. It is possible
that this high plaque burden predisposes elderly patients to no-reﬂow.
Secondly delayed presentation was a signiﬁcant predictor of no-
reﬂow and this is a potentially preventable factor. Delayed presentation
is associated with greater ischaemic injury which leads to oedema of
capillary bed, swelling of myocardial cells and neutrophil plugging [3].
It is well known from animal studies that longer duration of occlusion
of coronary artery is associated with no-reﬂow after reopening the ar-
tery [3]. In our study delayed presentation with a pain to balloon time
N360 min was associated with no-reﬂow. Previous studies have
shown that delayed presentation N6 h from symptom onset to be inde-
pendently associated with no-reﬂow [2,17]. However, studies using a
shorter cut-off of delayed presentation (b6 h from symptom onset) doTable 5
Independent predictors of no-reﬂow on multivariate analysis.
Variable Hazard ratio Conﬁdence interval p value
Thrombus score ≥4 2.28 1.50–3.55 b 0.0001
Symptom to balloon time N360 min 1.72 1.21–2.44 0.0024
Age N 60 years 1.53 1.08–2.18 0.018
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reﬂow [9,18]. Measures to educate the public in recognition of heart at-
tack symptoms and early presentation by ambulance to hospitalmay be
beneﬁcial. Continued efforts to minimise delays within the health sys-
tem due to diagnosis, transfer and intervention in STEMI patients may
also reduce the overall risk of no-reﬂow [19].
Thirdly, in our study thrombus score ≥4was an independent predic-
tor of no-reﬂow. A high thrombus burden commonly occurs in the set-
ting of an occluded infarct artery and both features have been found to
increase the risk of no reﬂow [17,20–22]. Distal embolization of throm-
botic debris can lead to poor myocardial perfusion, larger infarct size
and poor prognosis [23]. Another interesting observation was that 17%
of patients developed no-reﬂow immediately after stent implantation.
This can occur as stent implantation can dislodge athero-thrombotic de-
bris and cause distal embolization [24]. The observation of this phenom-
enon has led several groups to develop a strategy of deferred stenting in
selected STEMI cases [25–27]. In this strategy, ﬂow is restored using
thrombectomy and possibly balloon inﬂations and stenting are deferred
to allow the thrombus burden to decrease over a period of hours to days.
At the same time, this allows the microvasculature to recover [25]. A
meta-analysis of ﬁve non-randomised studies comparing immediate
versus deferred stenting showed that deferred stenting reduced the oc-
currence of no-reﬂow and distal embolization without an increase in
major bleeding or major adverse cardiac events [26]. Recently, a small
proof of concept trial randomised 101 STEMI patients with risk factors
for no-reﬂow such as age N65 years, occluded infarct artery, high
thrombus burden or presentation after 6 h to immediate stenting or de-
ferred stenting after a median time of 9 h [25]. There was a reduction in
the incidence of no-reﬂow and a follow-up cardiac MRI at 6 months
showed greater myocardial salvage in the deferred group which may
have prognostic signiﬁcance. There was no increase in bleeding in the
deferred group with prolonged antithrombotic treatment [25].
Considering that there is no evidence based treatment for no-reﬂow
once it has occurred, it is important to identify patients with the above
mentioned three risk factors of no-reﬂow, who may beneﬁt from
more targeted therapies such as deferred stenting ormore intensive an-
ticoagulant therapy. Larger randomised studies are needed to test the
strategy of deferred stenting.
5. Limitations
This is a single centre observational study, but the data apart from
ﬂow assessment was collected prospectively and the research staff
collecting data on clinical events was not aware of the occurrence of
no-reﬂow in patients. The assessment of coronary ﬂow was performed
by the TIMI ﬂow method which can be subjective, but this was per-
formed by a single experienced cardiologist in order tomaintain consis-
tency. Alsomost previous studies have used TIMI ﬂow as themethod for
assessing no-reﬂow [3]. Assessment of myocardial blush grade (MBG)
was not performed as most angiogram ﬁlms were not acquired long
enough to visualise the myocardial blush. Although TIMI ﬂow is less ac-
curate thanMBG inmeasuringmyocardial perfusion, it has been shown
to be a predictor of mortality in numerous studies and so remains a use-
ful marker that is practical and easy to measure in clinical practice [3].
Ejection fraction is a strong predictor of prognosis but was not included
in the multivariate analysis as this information was not known at the
time of presentation. It may be difﬁcult to assess the independent effect
of no-reﬂow in the absence of ejection fraction. However, these two pa-
rameters are associatedwith each other, as no-reﬂow leads to poor ejec-
tion fraction due to distal embolization andmyocardial infarction [3]. As
ejection fraction is usually not known at the time of presentation, no-
reﬂow serves as a useful alternativemarker to predict prognosis. Finally,
in ourmultivariate model, we did not include serologic markers such as
blood glucose, C-reactive protein (CRP) or brain natriuretic peptide
(BNP) that have been shown to be predictors of no-reﬂow in other stud-
ies, as this information was not routinely recorded in our database [3].However, we included clinical and angiographic variables that are avail-
able to the operator at the time of primary PCI. The three risk factors
identiﬁed in this study can be readily used to identify a patient at high
risk for no-reﬂow.
6. Conclusions
No-reﬂow occurred in 25% of STEMI patients undergoing primary
PCI and was more likely with older age, high thrombus burden and de-
layed presentation. No-reﬂowwas associatedwith a higher risk of death
at 12 month follow-up. As there is no effective treatment for no-reﬂow
once it has occurred, it is important to try and predict and prevent no-
reﬂow from occurring. In patients at high risk of no-reﬂow such as
those with older age, high thrombus burden or delayed presentation,
a strategy of deferred stenting and longer antithrombotic therapy may
be considered. These strategies require further conﬁrmation in clinical
trials.
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